Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

- PMLiVE

Priority review for Lilly’s ramucirumab in gastric cancer

Update comes as company posts improved revenue results

- PMLiVE

Roche signs biologics partnership with Samsung

Manufacturing deal follows investment in pharma firm's own capabilities

- PMLiVE

Amgen buys total filgrastim rights from Roche

Wrests control of white blood cell stimulator franchise

Google Glass passes clinical ‘proof of concept’

Philips-Accenture project trials patient data delivery via smart-glasses

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

Public unaware of main cause of liver cancer

Janssen-backed survey finds one in six people is aware of viral hepatitis role in the disease

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

Kidney cancer campaign launches in UK

The ‘Be Clear on Cancer’ campaign is aimed at raising awareness of the symptoms of bladder and kidney cancers

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

Roche Basel Switzerland

Roche invests $879m in its biologics future

Expects to create around 500 new jobs in Switzerland, Germany and the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links